Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

PCI before TAVR? In older CAD patients, deferral may be the best approach
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Interventional cardiologist Roxana Mehran elected ACC president
A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.
New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight
The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.
Catheter-based treatment linked to major benefits for intermediate-risk PE
New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Interventional cardiologist Roxana Mehran, MD, officially started her one-year term as the president of the American College of Cardiology (ACC) on the closing day of ACC.26, the group’s annual conference in New Orleans.

Interventional cardiologist Roxana Mehran elected ACC president

A prominent figure in the fields of interventional cardiology and women’s health is now leading the American College of Cardiology.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

‘Practice-changing’ interventional cardiology research grabs ACC.26 spotlight

The second day of the American College of Cardiology’s annual conference started with a series of highly anticipated interventional cardiology trials.

Stavros V. Konstantinides, MD, PhD, presenting data at ACC.26

Catheter-based treatment linked to major benefits for intermediate-risk PE

New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.

William P. Shutze, MD, FACS, secretary of the Society of Vascular Surgery (SVS), a vascular surgeon with Texas Vascular Associates in Plano, Texas, and a clinical associate professor of medicine at Texas A&M College of Medicine, explained the role of vascular surgeons in peripheral artery disease (PAD) and critical limb ischemia (CLI).

Getting vascular surgeons more involved leads to key improvements for PAD patients

Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?

Philips has secured U.S. Food and Drug Administration (FDA) clearance for EchoNavigator R5.0 with DeviceGuide, the company’s artificial intelligence (AI)-enabled software for mitral transcatheter edge-to-edge repair (M-TEER).

FDA clears new AI software for mitral valve repair

Philips worked closely with Edwards Lifesciences to develop the new software.

intrasaccular flow disruptor coronary aneurysm

Cardiologists use endovascular device for brain aneurysms to treat high-risk heart patients

A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.